CSL Limited (CSL Behring is the largest division)
↗Melbourne, Australia (corporate); King of Prussia, USA (CSL Behring)
CSL Limited is a global biotechnology company headquartered in Melbourne, Australia, with over 32,000 employees delivering lifesaving therapies to patients in more than 100 countries. The company operates through four main divisions: CSL Behring (plasma-derived and recombinant therapeutics), CSL Seqirus (influenza vaccines), CSL Vifor (iron deficiency and nephrology), and CSL Plasma (world's largest plasma collection network with 300+ centers). CSL Behring, headquartered in King of Prussia, Pennsylvania, is one of the world's leading biotherapeutics companies specializing in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Biotechnology/Pharmaceuticals
Sub-Industry:Plasma-derived therapies, Recombinant proteins, Cell and gene therapy, Vaccines, Iron deficiency and nephrology
SIZE & FINANCIALS
Employees:10000+
Revenue:$13-15B+
Founded:1916
Ownership:public
Status:operating
FUNDING
Stage:Public Company
STOCK
Exchange:ASX (Australian Securities Exchange); also trades as CSLL.Y on OTC
Ticker:ASX:CSL
Market Cap:AUD $83.43 billion (approximately USD $58.39 billion as of January 2026)
PIPELINE
Stage:Phase 1 through Commercial
Lead Drug Stage:Commercial and Phase 3
Modalities:Plasma-derived proteins, Recombinant proteins, Monoclonal antibodies (mAb), Gene therapy (AAV), Cell and gene therapy, Influenza vaccines, mRNA technology
Active Trials:50
Trial Phases:Phase 1: 8 | Phase 2: 12 | Phase 3: 8 | Phase 4: 22
FDA Approvals:40
EMA Approvals:35
CORPORATE STRUCTURE
Subsidiaries:CSL Behring, CSL Seqirus, CSL Vifor, CSL Plasma
Key Partnerships:Arcturus Therapeutics - exclusive license to sa-mRNA technology, ASLAN Pharmaceuticals - licensing collaboration, Travere Therapeutics - FILSPARI development partnership, VarmX - option to acquire lead hemostasis drug VMX-C001, Legrand - rSIM technology partnership (July 2025), aTyr Pharma - research collaboration
COMPETITION
Position:Leader
Competitors:Baxter International, Grifols, Octapharma, Kedrion Biopharma, Takeda Pharmaceutical, Bio Products Laboratory, LFB Group, Emergent BioSolutions +2 more
LEADERSHIP
Key Executives:
Dr. Paul McKenzie - Chief Executive Officer and Managing Director
Paul Perreault - Former CEO (retired 2023)
Bill Campbell - Executive Vice President and Chief Commercial Officer
Paul McKenzie - Chief Operating Officer
Tricia Stewart - Senior VP and General Manager, Kankakee site
J Newsom - Senior VP, Chief Information Officer
Scientific Founders:Emil von Behring (founder of Behringwerke, 1904, Nobel Prize winner), Commonwealth Serum Laboratories founders (established 1916, Australia)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CSL Limited (CSL Behring is the largest division). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.